ELSOHLY LABORATORIES, INC.

Basic Information

5 INDUSTRIAL PARK DR
OXFORD, MS, 38655-

Company Profile

n/a

Additional Details

Field Value
DUNS: 157239245
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Orally Active Formulations of DHA Dimers for the Treatment of Infectious Diseases

    Amount: $205,514.00

    DESCRIPTION (provided by applicant): The natural product artemisinin is a sesquiterpene endoperoxide with known anti-malarial activity against both chloroquine-sensitive and chloroquine-resistant stra ...

    STTR Phase I 2013 Department of Health and Human Services
  2. Development of Tetrahydrocannabinol Prodrugs for Topical Treatment of Glaucoma

    Amount: $167,381.00

    DESCRIPTION (provided by applicant): Currently, FDA approved clinical applications of 9-Tetrahydrocannabinol (THC) include control of nausea and vomiting associated with chemotherapy and for appe ...

    STTR Phase I 2011 Department of Health and Human Services
  3. Compositions for Prevention/Prophylactic Treatment of Poison Ivy Dermatitis

    Amount: $739,218.00

    DESCRIPTION (provided by applicant): Poison ivy/oak contact dermatitis is the most prevalent skin allergy in the United States, affecting gt50% of the adult population. The condition is the major cau ...

    STTR Phase II 2009 Department of Health and Human Services
  4. Transmucosal Intra-Oral Drug Delivery System for THC

    Amount: $743,609.00

    DESCRIPTION (provided by applicant): Delta-9-Tetrahydrocannabinol (THC), the active ingredient in the cannabis plant, has a wide range of pharmacological properties of therapeutic value. The drug has ...

    STTR Phase II 2008 Department of Health and Human Services
  5. Compositions for Prevention/Prophylactic Treatment of Poison Ivy Dermatitis

    Amount: $100,074.00

    DESCRIPTION (provided by applicant): The long term objectives of this proposal are aimed at the development of new composition(s) to be used for the prophylactic treatment/prevention of poison ivy con ...

    STTR Phase I 2006 Department of Health and Human Services
  6. Transmucosal Intra-Oral Drug Delivery System for THC

    Amount: $99,986.00

    DESCRIPTION (provided by applicant): The overall goal of this research project is to develop an effective, hot-melt extruded "Transmucosal Matrix Patch" (TMP) as a delivery system for Delta-9-Tetrahyd ...

    STTR Phase I 2003 Department of Health and Human Services
  7. SYNTHESIS OF CONJUGATED METABOLITES OF BUPRENOPHINE

    Amount: $93,816.00

    The development of maintenance treatment for subjects with addictive behavior is an important public health issue. Buprenorphine, a promising new drug for the treatment of opiates addition, has been w ...

    SBIR Phase I 2002 Department of Health and Human Services
  8. N/A

    Amount: $0.00

    N/A

    STTR Phase I 2000 Department of Health and Human Services
  9. N/A

    Amount: $276,333.00

    N/A

    STTR Phase II 2000 Department of Health and Human Services
  10. N/A

    Amount: $0.00

    N/A

    SBIR Phase I 2000 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government